Skip to main content
Download PDF

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Virology Journal volume 15, Article number: 137 (2018) Cite this article

The Original Article was published on 24 July 2018

Correction

Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China. So, in the originally published article [1], the “Ad-HBV” appeared throughout the whole paper for 41 times should be replaced by “T101”.

Additionally, in the “Acknowledgements” section in the originally published article, “The Ad-HBV were a kind gift from Xia Meng (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China). We want to thank Zhiming Wang and Xiaomin Wang (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China) for teaching neutralization activity detection of anti-Ad antibodies” should be replaced by “We want to thank Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., to provide us the opportunity to participate in the non-clinical safety assessment of T101, and most of the research work appeared in this paper came from the non-clinical safety assessment of T101”.

Reference

  1. Zhang XF, et al. Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates. Virol J. 2018;15:111. https://doi.org/10.1186/s12985-018-1026-3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing, 211800, China

    Xuefeng Zhang, Jing Wang, Jing Lu, Rongrong Li & Shuli Zhao

  2. Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China

    Shuli Zhao

Authors
  1. Xuefeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rongrong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuli Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuli Zhao.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Wang, J., Lu, J. et al. Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates. Virol J 15, 137 (2018). https://doi.org/10.1186/s12985-018-1049-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12985-018-1049-9

Virology Journal

ISSN: 1743-422X